The July 2026 FDA PCAC Peptide Vote: What It Does and Doesn't Change for US Researchers

• ·On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides for possible inclusion on the 503A bulks list.[1][6]
• ·Six were recommended for inclusion: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. Emideltide (DSIP) was not.[1]
• ·The votes are advisory and non-binding. No peptide is formally added to the list until the FDA completes notice-and-comment rulemaking, which may run into 2027 or beyond.[1][7]
• ·The vote concerns pharmacy compounding. It does not approve any peptide as a drug and does not change how research-use-only (RUO) reagents are regulated.

The Pharmacy Compounding Advisory Committee is an outside panel the FDA consults on compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Section 503A lets licensed pharmacies compound drugs for individual patients, but only from bulk drug substances that meet one of three tests: they comply with a USP or NF monograph, they are a component of an FDA-approved drug, or they appear on the FDA's "503A bulks list". The PCAC advises the agency on which substances should be added to that list.[5][6]

Each nominated substance is weighed against four criteria the FDA set by regulation in 2019: its physical and chemical characterization, any safety issues raised by its use in compounding, the available evidence of effectiveness, and its historical use in compounding. The criteria are balanced against one another substance by substance, and the committee then votes on whether the FDA should add the substance to the list.[6]

Research Material

The committee split on every substance, and several of the margins were narrow. An 8 to 6 vote is a recommendation, not a consensus. FDA scientists had recommended against inclusion for all seven, citing insufficient safety, effectiveness and characterization information, and some members who voted yes conditioned their support on safeguards such as authorized ingredient sourcing and adverse-event reporting.[1][6]

Across the two-day public meeting, members voted as follows. Each vote covered both the free base and the acetate form.[1]

• ·BPC-157 (July 23). 8 in favor, 6 against, 1 abstention. Recommended for inclusion.
• ·KPV (July 23). 8 in favor, 6 against, 1 abstention. Recommended for inclusion.
• ·TB-500 (July 23). 8 in favor, 6 against, 1 abstention. Recommended for inclusion.
• ·MOTS-c (July 23). 7 in favor, 5 against, 2 abstentions. Recommended for inclusion.
• ·Emideltide, DSIP (July 24). 6 in favor, 7 against, 1 abstention. Not recommended.
• ·Epitalon (July 24). 7 in favor, 4 against, 1 abstention. Recommended for inclusion.
• ·Semax (July 24). 8 in favor, 5 against, 1 abstention. Recommended for inclusion.

Amino Acid Sequence

Chemical Structure

Three distinctions matter for anyone reading headlines about the vote.

First, the vote is advisory. The FDA can accept, reject or delay acting on a PCAC recommendation, although the agency noted at the meeting that it rarely diverges from one. Legal commentators expect it to begin rulemaking, but the timing is open and could stretch across multiple years.[1][2]

Second, the 503A bulks list is a compounding pathway, not a drug approval. Even if BPC-157 is eventually added, it would remain an unapproved substance. The listing would only let a licensed pharmacy compound it for an individual patient under a prescription.

Third, this sits on top of an earlier change. In April 2026 the FDA removed twelve peptides, including all seven reviewed in July, from its Category 2 "significant safety risks" list after their nominations were withdrawn.[2] Removal from Category 2 did not make those substances eligible for compounding either. We cover that change in a separate post on the April 2026 Category 2 removals.

Put together, the limits of the vote are these:

• ·It is non-binding. The committee advises, it does not decide. No final FDA determination has been issued and none of the six peptides appears in 21 CFR 216.23.
• ·It requires a further step. Addition to the 503A Bulks List requires formal action by the Secretary of Health and Human Services, which had not occurred as of publication.
• ·It does not make the compound an FDA-approved drug, and it establishes nothing about efficacy.
• ·It does not legitimize research-chemical retail. A compounding-list decision concerns licensed pharmacists preparing patient-specific prescriptions under Section 503A, which is a different channel entirely from research material sold in vials.

For laboratories purchasing peptides as research reagents, the practical picture is unchanged:

• ·RUO reagents are not compounded drugs. The PCAC process governs pharmacies. A research reagent supplier is neither a pharmacy nor a 503B outsourcing facility.
• ·The FDA still judges RUO sellers by intended use. In warning letters dated March 31, 2026, the agency concluded that "Research Use Only" labels did not outweigh website content showing that the products were intended for human use.[3][4] A favorable PCAC vote does not loosen that standard. Our explainer on what research use only means in the US covers this in detail.
• ·Characterization matters more, not less. FDA scientists cited insufficient characterization in recommending against every substance, and commentators expect further submissions on peptide identity and purity to carry particular weight as the agency decides what to do next.[1] Labs should expect suppliers to provide batch-specific, third-party analytical data, and should treat material without it as uncharacterized.

Every BPC-157 lot we list is tested by an independent laboratory before sale, Janoshik Analytical for most Eppix lots, and each certificate names the laboratory that issued it. Results are published as the laboratory reported them: most lots measure above 99% HPLC purity, an occasional lot comes back around 98% and is published rather than left out, and measured content against the label is reported as its own figure, separate from purity.

The certificate for the current lots is below, and every lot is listed on our certificates of analysis page. The compound itself is on the BPC-157 product page.

Published Certificate

Select strength

10mg12mg20mg

Batch

BPC-CA-25L-01

Purity (HPLC)

99.765%

Measured content

10.98 mglabeled 10 mg

Laboratory

Janoshik

Verify on the lab’s own databaseAll published certificates

Three things will tell US researchers more than the vote did. We will update this post as the FDA acts.

• ·FDA rulemaking notices in the Federal Register proposing additions to the 503A bulks list.[1]
• ·A second PCAC review of the five remaining peptides removed from Category 2 (LL-37, dihexa, injectable GHK-Cu, PEG-MGF and Melanotan II), expected before the end of February 2027.[1][2]
• ·Further warning letters to online sellers, which remain the clearest signal of how the FDA views the RUO market.

Available at Eppix Labs

BPC-157

10mg · 12mg · 20mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $49.99 USDIn stock